C

Cellbricks

Develops 3D tissue implants for organ replacement, aiming to advance engineered tissue therapies for patients needing restorative treatments.

Deep Tech
Tissue engineering
Total Raised
€10M
Headquarters
Berlin, Germany
Share

Overview

Cellbricks is developing 3D tissue implants intended to support organ replacement, positioning the company in tissue engineering and regenerative medicine rather than software-led AI. Its work targets healthcare markets where engineered implants could address organ or tissue failure. The company raised a €10M seed round on March 25, 2026, backed by Silicon Roundabout, to advance its implant and organ replacement programs. The funding context indicates an early-stage deep-tech company focused on translating 3D tissue fabrication into therapeutic applications.

Funding History

1 round · Mar 2026
€10M
Total Raised
1
Cumulative: €10M

Silicon Roundabout backs Cellbricks’ €10M round to advance 3D tissue implants and organ replacement

Silicon Roundabout Ventures (Lead)SPRINDACT Venture Partners
Source

Frequently Asked Questions

How much funding does AI Funding track for Cellbricks?
AI Funding tracks €10M for Cellbricks across 1 funding round in this database.
Who are Cellbricks's investors?
Cellbricks's investors include Silicon Roundabout Ventures, SPRIND, ACT Venture Partners.
What does Cellbricks do?
Cellbricks is developing 3D tissue implants intended to support organ replacement, positioning the company in tissue engineering and regenerative medicine rather than software-led AI. Its work targets healthcare markets where engineered implants could address organ or tissue failure. The company raised a €10M seed round on March 25, 2026, backed by Silicon Roundabout, to advance its implant and organ replacement programs. The funding context indicates an early-stage deep-tech company focused on translating 3D tissue fabrication into therapeutic applications.
Where is Cellbricks headquartered?
Cellbricks is headquartered in Berlin, Germany.